Apokyn Related Published Studies
Well-designed clinical trials related to Apokyn (Apomorphine)
Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. [2009.05]
Apomorphine nodules in Parkinson's disease: best practice considerations. [2008.10]
Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. [2008.09]
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2008.03]
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. [2008.02]
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2008]
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial. [2007.12.15]
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2007.12.11]
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial. [2007.12]
Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial. [2007.09.25]
Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction--an open, randomized cross-over study with flexible dosing. [2007.02.26]
Betamethasone does not prevent nausea and vomiting induced by the dopamine-agonist apomorphine. [2006.04]
Comparison of the effect of sildenafil and apomorphine SL on nocturnal erections in healthy volunteers: a placebo-controlled study. [2005.04]
Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. [2005.01.03]
Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. [2005.01]
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. [2004.09]
Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. [2004.06]
An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. [2004.06]
Placebo-controlled study on efficacy and safety of daily apomorphine SL intake in premenopausal women affected by hypoactive sexual desire disorder and sexual arousal disorder. [2004.05]
Pharmacokinetic-pharmacodynamic study of apomorphine's effect on growth hormone secretion in healthy subjects. [2003.08]
Apomorphine-induced brain modulation during sexual stimulation: a new look at central phenomena related to erectile dysfunction. [2003.06]
Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction. [2003.04]
Brain activation patterns during video sexual stimulation following the administration of apomorphine: results of a placebo-controlled study. [2003.04]
The apomorphine test: a biological marker for heroin dependence disorder? [2002.10]
A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. [2002.03]
Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction. [2002.02]
Cardiovascular safety of sublingual apomorphine in patients on stable doses of oral antihypertensive agents and nitrates. [2001.10.01]
A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. [2001.09]
Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. [2001.05]
The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. [2001.03]
Effect of apomorphine on motor and cognitive function in melancholic patients: a preliminary report. [2000.12.27]
Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. [2000.07]
Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. [2000.01.25]
Electroencephalographic characterization of brain dopaminergic stimulation by apomorphine in healthy volunteers. [1999]
Growth hormone response to placebo, apomorphine and growth hormone releasing hormone in abstinent alcoholics and control subjects. [1998.09.01]
A double-blind, placebo-controlled study of intranasal apomorphine spray as a rescue agent for off-states in Parkinson's disease. [1998.09]
Pharmacodynamics of levodopa coadministered with apomorphine in parkinsonian patients with end-of-dose motor fluctuations. [1998.03]
Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. [1997.12]
Apomorphine induced alteration in corneofundal potentials in depression. [1997.07]
A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. [1996.11]
Acute challenge with apomorphine in Huntington's disease: a double-blind study. [1995.10]
Prefrontal cortical and hippocampal modulation of haloperidol-induced catalepsy and apomorphine-induced stereotypic behaviors in the rat. [1995.08.15]
Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. [1995.07]
The apomorphine test in heroin addicts. [1995.06]
Pen injected apomorphine against off phenomena in late Parkinson's disease: a double blind, placebo controlled study. [1995.06]
The influence of propofol on vomiting induced by apomorphine. [1995.05]
Video assessment of yawning induced by sublingual apomorphine in migraine. [1994.10]
A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. [1993.09]
Reproducibility of motor effects induced by successive subcutaneous apomorphine injections in Parkinson's disease. [1993.04]
Apomorphine test for dopaminergic responsiveness: a dose assessment study. [1993.04]
Low-dose apomorphine challenge in tardive akathisia. [1993.03]
Selective effects of low doses of apomorphine on spatiotemporal contrast sensitivity in healthy volunteers: a double-blind placebo-controlled study. [1991.11]
Apomorphine-induced blinking and yawning in healthy volunteers. [1990.11]
The effect of apomorphine on regional cerebral blood flow in schizophrenia. [1989.09]
Well-designed clinical trials possibly related to Apokyn (Apomorphine)
Foot-tapping rate as an objective outcome measure for Parkinson disease clinical trials. [2009.03]
Induction of tolerance of dopaminergic responses in man. [2008.08]
Growth hormone response to different consecutive stress stimuli in healthy men: is there any difference? [2007.06]
[Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)] [2007]
Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. [2004.01]
Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson's disease. [2003.06]
Lisuride, a dopamine D2 receptor agonist, and anticraving drug expectancy as modifiers of relapse in alcohol dependence. [2002.02]
Dopaminergic sensitivity and prediction of antidepressant response. [2000.06]
Dopaminergic and cholinergic control of arginine-vasopressin secretion in type I diabetic men. [1995.06]
Fluctuations in Parkinson's disease. Pathogenetic significance of levodopa's cerebral pharmacokinetics and pharmacodynamics. [1995]
Effect of the placebo control condition in neuroendocrine challenge studies. [1994.06]
Activity of a new antiemetic agent: alizapride. A randomized double-blind crossover controlled trial. [1988]
Other research related to Apokyn (Apomorphine)
Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. [2009.10.03]
Low dose apomorphine induces context-specific sensitization of hypolocomotion without conditioning: support for a new state dependent retrieval hypothesis of drug conditioning and sensitization. [2009.08]
Apomorphine and levodopa infusion therapies for advanced Parkinson's disease: selection criteria and patient management. [2009.06]
Human biodistribution and dosimetry of the D2/3 agonist 11C-N-propylnorapomorphine (11C-NPA) determined from PET. [2009.05]
The duration of the motor response to apomorphine boluses is conditioned by the length of a prior infusion in Parkinson's disease. [2009.04.15]
Apomorphine in the treatment of Parkinson disease and other movement disorders. [2009.04]
Effect of sublingual medication of sildenafil citrate/ apomorphine on sexual behaviour of male rats. [2009.04]
Treatment of Parkinson's disease could be regulated by movement sensors: subcutaneous infusion of varying apomorphine doses according to the intensity of motor activity. [2009.04]
Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease. [2009.03]
Fast awakening from minimally conscious state with apomorphine. [2009.02]
Ultrasound treatment of cutaneous side-effects of infused apomorphine: a randomized controlled pilot study. [2009.01.15]
Use of apomorphine in Parkinson's disease. [2008.12]
5-HT(1A) and 5-HT(1B) receptors in the ventrolateral striatum differentially modulate apomorphine-induced jaw movements in rats. [2008.12]
Safety and efficacy of an ocular insert for apomorphine-induced emesis in dogs. [2008.10]
Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. [2008.09.24]
Apomorphine-induced turning behavior in 6-hydroxydopamine lesioned rats is increased by histidine and decreased by histidine decarboxylase, histamine H1 and H2 receptor antagonists, and an H3 receptor agonist. [2008.09]
Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. [2008.06.15]
Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. [2008.06.04]
Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. [2008.05]
[Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement] [2008.04]
Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease. [2008.04]
Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. [2008.02.12]
Apomorphine effects on episodic memory in young healthy volunteers. [2008.01.15]
Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label study. [2008]
An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. [2008]
Effects of acute and chronic apomorphine on sex behavior and copulation-induced neural activation in the male rat. [2007.12.08]
Behavioral responses to methylphenidate and apomorphine in rats exposed neonatally to bisphenol-A. [2007.12]
Low doses of apomorphine transiently reduce locomotor activity in MPTP-treated mice. [2007.11.27]
Apomorphine therapy in Parkinson's disease: a review. [2007.11]
Exposure to the phytoestrogen daidzein attenuates apomorphine-induced penile erection concomitant with plasma testosterone level reduction in dose- and time-related manner in adult rats. [2007.09]
[Apomorphine and erectile dysfunction] [2007.09]
Human embryonic stem cell-derived neural precursor transplants attenuate apomorphine-induced rotational behavior in rats with unilateral quinolinic acid lesions. [2007.08.09]
Apomorphine in the treatment of Parkinson's disease. [2007.08]
Growth hormone response to low-dose apomorphine in restless legs syndrome. [2007.08]
Apomorphine effects on episodic memory in young healthy volunteers. [2007.07.26]
|
